
Loading, please wait...

Loading, please wait...

Recent scientific breakthroughs have highlighted the KDM8 histone demethylase as a critical regulator of the DNA damage response. While researchers initially characterized it for its activity on H3K36me2, scientists now recognize KDM8 as a multifunctional hydroxylase. New studies identified this enzyme as a key factor in how cells manage the γH2AX response following ionizing radiation exposure. Specifically, KDM8 modulates the delicate choice between two primary repair pathways: homologous recombination (HR) and non-homologous end joining (NHEJ). This regulation ensures that cells maintain genomic integrity despite constant environmental threats.
Experimental evidence indicates that KDM8 levels directly dictate the efficiency of homologous recombination. For example, the depletion of this protein leads to a measurable increase in HR activity. Conversely, overexpressing the enzyme significantly reduces HR capacity. This shift occurs because KDM8 interacts directly with Rad51, a vital recombinase involved in DNA strand exchange during the repair process. Interestingly, the enzyme's impact on repair pathway choice remains largely independent of its traditional demethylase function. Furthermore, these changes do not appear to stem from alterations in the cell cycle, suggesting a direct regulatory role in DNA repair machinery.
Understanding these epigenetic mechanisms offers potential insights into modern cancer therapy. Although KDM8 influences the repair pathway balance, current findings suggest it does not alter overall cellular sensitivity to ionizing radiation or chemotherapeutic agents like camptothecin. However, the discovery of the KDM8-Rad51 interaction provides a novel target for future research into treatment resistance. Therefore, clinical researchers should continue to investigate if modulating KDM8 can sensitize specific tumors to DNA-damaging treatments. Such insights could eventually lead to more personalized oncology protocols in the future.
KDM8 acts as a regulatory switch between two main repair pathways. Higher levels of KDM8 decrease homologous recombination and promote non-homologous end joining, while low levels of the enzyme increase recombination activity.
Yes, sophisticated imaging experiments in living cells have demonstrated a direct interaction between KDM8 and the recombinase Rad51 following DNA damage, particularly after exposure to camptothecin.
The research suggests that the influence of KDM8 on the balance between HR and NHEJ is partly independent of its catalytic demethylase activity, pointing toward a more complex structural or signaling role.
Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice or a professional relationship. Always seek the advice of a qualified healthcare provider for any questions regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.
References
Fages J et al. Control of DNA double-strand break repair by the KDM8 histone demethylase. Cell Cycle. 2026 Dec undefined. doi: 10.1080/15384101.2026.2659192. PMID: 42001401.
Fernandez A et al. Epigenetic Mechanisms in DNA Double Strand Break Repair: A Clinical Review. Front Mol Biosci. 2021;8:5440. doi: 10.3389/fmolb.2021.685440.
Mancini E et al. JMJD-5/KDM8 regulates H3K36me2 and is required for late steps of homologous recombination and genome integrity. PLOS Genet. 2017;13(2):e1006632. doi: 10.1371/journal.pgen.1006632.
"
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.


KDM8 histone demethylase regulates DNA double-strand break repair by balancing homologous recombination and NHEJ through direct interaction with Rad51....
6 months ago

Explore vital recurrent stroke predictors in lacunar stroke patients managed with intensive blood pressure lowering. This analysis examines trial findings from SPS3 to uncover residual vascular risks, metabolic factors, and targeted secondary prevention strategies for high-risk neurological patients.
Today

A comprehensive scoping review synthesises evidence linking prenatal maternal mental health to long-term offspring neurodevelopment, evaluating neuroendocrine, inflammatory, and epigenetic pathways while highlighting clinical screening and future research priorities.
Today

The Directorate General of Health Services directs Indian states to halt the hazardous reuse and reprocessing of single-use medical devices. Discover regulatory implications under the Drugs and Cosmetics Act, critical infection risks, legal liabilities, and operational changes required across clinical specialties.
Today

Mitochondria-targeted nanoparticles self-assembled from EGCG and L-glutamic acid effectively restore mitochondrial homeostasis, suppress synovial inflammation, and attenuate chondrocyte senescence in osteoarthritis, offering a promising disease-modifying nanotherapy.
Today

India is advancing preventive healthcare by integrating genomics, artificial intelligence, and quantum technologies. With the SANGAM programme sequencing one million Indian genomes, clinicians can unlock personalized therapies, detect cardiometabolic risks early, and curb the burden of diabetes and heart disease.
Today